On January 20, 2015 European biotechnology company Valneva SE ("Valneva") and UK company BliNK Therapeutics Ltd ("BliNK Therapeutics") reported the closing of the transaction creating BliNK Biomedical SAS, a private company specialised in the discovery of innovative monoclonal antibodies as announced on December 11th, 2014 (Press release, Cancer Research Technology, JAN 20, 2015, View Source [SID1234523212]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new company is owned by Valneva, Kurma Biofund I (founding investor of BliNK Therapeutics), funds managed by Idinvest Partners, Cancer Research Technology (CRT) and BliNK Therapeutics’ founders.

BliNK Therapeutics’ technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at Cancer Research UK’s London Research Institute.